α-Synuclein Aggregation in Treatment of Parkinson's Disease
Por um escritor misterioso
Descrição
Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.
Alpha Synuclein in Parkinson's Disease Diagnostics
Cellular models of alpha‐synuclein toxicity and aggregation - Delenclos - 2019 - Journal of Neurochemistry - Wiley Online Library
Current Progress in the Development of Probes for Targeting α-Synuclein Aggregates
Distribution of α-Synuclein Aggregation in the Peripheral Tissues
Monitoring α-synuclein Aggregation Induced by Preformed α-synuclein Fibrils in an In Vitro Model System
Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease
Interactions between iron and α-synuclein pathology in Parkinson's disease - ScienceDirect
Rescue of α-synuclein aggregation in Parkinson's patient neurons by synergistic enhancement of ER proteostasis and protein trafficking - ScienceDirect
α‐Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives - Alzghool - 2022 - Movement Disorders - Wiley Online Library
Frontiers Lovastatin Alleviates α-Synuclein Aggregation and Phosphorylation in Cellular Models of Synucleinopathy
de
por adulto (o preço varia de acordo com o tamanho do grupo)
